RedHill Biopharma (RDHL) EBITDA (2012 - 2023)

RedHill Biopharma (RDHL) has reported EBITDA for 12 consecutive years, with $53.8 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, EBITDA rose 486.88% year-over-year to $53.8 million in Q2 2023; TTM through Jun 2023 was -$44.0 million, a 55.32% increase from a year earlier, with the FY2025 full-year figure at -$7.9 million, down 22.66% from the prior year.
• EBITDA was $53.8 million for Q2 2023 at RedHill Biopharma, up from -$29.1 million in the prior quarter.
• Over five years, EBITDA peaked at $53.8 million in Q2 2023 and troughed at -$141.6 million in Q4 2021.
• A 5-year average of $421000.0 and a median of $12.4 million in 2019 frame the typical range for EBITDA.
• Across the five-year window, EBITDA sank 818.34% in 2021 and soared 486.88% in 2023, its largest moves.
• Over 5 years, EBITDA stood at $11.8 million in 2019, then jumped by 67.53% to $19.7 million in 2020, then slumped by 818.34% to -$141.6 million in 2021, then surged by 46.5% to -$75.7 million in 2022, then jumped by 170.97% to $53.8 million in 2023.
• The last three EBITDA figures came in at $53.8 million (Q2 2023), -$29.1 million (Q1 2023), and -$75.7 million (Q4 2022), per Business Quant data.